RBC Capital Reiterates Outperform Rating on BeOne Medicines (ONC)
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $408.00 price target on BeOne Medicines (NASDAQ: ONC).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


